论文部分内容阅读
目的 :观察ELFP方案治疗晚期胃癌的疗效和毒副作用。方法 :39例晚期胃癌患者接受PDD 30mg静滴 ,第 1～ 4天 ;VP - 16 10 0mg静滴 ,第 1～ 5天 ;CF 10 0mg静滴 ,第 1～ 5天 ;5 -Fu 75 0mg静滴 ,第 1～ 5天 ;2 1天为 1周期。结果 :可评价疗效患者 31例 ,总有效率 5 8% ,完全缓解率 16 1% ,可评价毒性患者 39例 ,白细胞减少发生率 79 5 % (Ⅲ度～Ⅳ度仅 5 1% ) ,血红蛋白减少和血小板减少发生率分别为 15 4%和 33 3% ,其它毒副反应少见。结论 :ELFP方案治疗晚期胃癌疗效肯定 ,毒性较低 ,值得继续研究。
Objective: To observe the efficacy and side effects of ELFP regimen in the treatment of advanced gastric cancer. Methods: Thirty-nine patients with advanced gastric cancer underwent intravenous infusion of PDD 30 mg intravenously for 1 to 4 days. VP-16 10 0 mg intravenously for 1 to 5 days. CF 10 0 mg intravenously for 1 to 5 days. Intravenous infusion, the first 1 to 5 days; 21 days for a period. Results: Among 31 evaluable patients, the total effective rate was 58%, the complete remission rate was 16.1%, 39 patients could be evaluated for toxicity, the incidence of leukopenia was 79.5% (Ⅲ ° ~ Ⅳ only 51%), hemoglobin The incidence of thrombocytopenia and thrombocytopenia were 15 4% and 33 3%, respectively. Other toxic and side effects were rare. Conclusion: The efficacy of ELFP regimen in the treatment of advanced gastric cancer is low and its toxicity is low. It is worth further study.